Disease · MONDO_0018906

follicular lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. follicular lymphoma. Diseases, record MONDO_0018906. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018906

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: follicular lymphoma; Open Targets
Open Targets ID: MONDO_0018906; Open Targets
Other names: follicle center lymphoma, follicle centre lymphoma, follicular center cell lymphoma, follicular centre cell lymphoma, follicular non-Hodgkin lymphoma, follicular non-Hodgkin's lymphoma, lymphoma, follicular center cell, lymphoma, follicular centre cell, lymphoma, follicular, malignant; Open Targets
Disease Ontology: DOID:0050873; Disease Ontology
MeSH: D008224; MeSH
NCI Thesaurus: C3209; NCI Thesaurus
Orphanet: ORPHA:545; Orphanet
Highest stage of its drugs: Approval, for 17 of its 209 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs209

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LENALIDOMIDE	CHEMBL848	Small molecule	Approval	EMA Human Drugs	67	64	64	Drugs and targets
OBINUTUZUMAB	CHEMBL1743048	Antibody	Approval	DailyMed and PMDA	65	63	63	Drugs and targets
MOSUNETUZUMAB	CHEMBL4297788	Antibody	Approval	EMA Human Drugs, FDA, PMDA and TTD	27	23	23	Drugs and targets
IBRITUMOMAB TIUXETAN	CHEMBL1201606	Antibody	Approval	EMA Human Drugs, at withdrawal	21	20	20	Drugs and targets
TAZEMETOSTAT	CHEMBL3414621	Small molecule	Approval	TTD	19	18	18	Drugs and targets
EPCORITAMAB	CHEMBL4650393	Antibody	Approval	PMDA	17	15	15	Drugs and targets
DUVELISIB	CHEMBL3039502	Small molecule	Approval	TTD	13	10	10	Drugs and targets
COPANLISIB	CHEMBL3218576	Small molecule	Approval	TTD	8	7	7	Drugs and targets
LISOCABTAGENE MARALEUCEL	CHEMBL4297236	Gene	Approval	EMA Human Drugs	9	6	6	Drugs and targets
UMBRALISIB	CHEMBL3948730	Small molecule	Approval	TTD	7	6	6	Drugs and targets

1 to 10 of 209

See all 209 drugs

Targets226

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	14	B-lymphocyte antigen CD20 binding agent	Approval	https://conductscience.org/library/genes/931	Drugs and targets
PIK3CD	PI3-kinase class I	12	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Approval	https://conductscience.org/library/genes/5293	Drugs and targets
BTK	Tyrosine-protein kinase BTK	8	Tyrosine-protein kinase BTK inhibitor	Phase 3	https://conductscience.org/library/genes/695	Drugs and targets
TUBA1A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 226

See all 226 targets

Trials526

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01332968	A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)	Phase 3	1,401	2017-06-07	Non-Hodgkin's Lymphoma	BENDAMUSTINE, CYCLOPHOSPHAMIDE, DOXORUBICIN, OBINUTUZUMAB, PREDNISONE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01476787	Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma	Phase 3	1,030	2025-05-14	Follicular Lymphoma	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01724021	A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a	Phase 3	743	2016-08-29	Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00312845	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Phase 3	676	2011-07-26	Non-Hodgkin's Lymphoma	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT04680052	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.	Phase 3	654	2025-04-04	Follicular Lymphoma, Marginal Zone Lymphoma	LENALIDOMIDE, RITUXIMAB, TAFASITAMAB	Its record names the disease	ClinicalTrials.gov
NCT01419665	GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)	Phase 3	629	2021-05-14	Follicular Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00006721	S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma	Phase 3	571	2013-02-26	Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, TOSITUMOMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT02536664	Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants		505	2015-11-06	Follicular Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01996865	Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.	Phase 3	503	2025-07-10	Lymphoma, Non-Hodgkin	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00719472	A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)	Phase 3	451	2012-06-26	Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 526

See all 526 trials

Comparisons in its trials154

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause	111 of 692	104 of 698	1,390	NCT01332968	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	309 of 692	361 of 698	1,390	NCT01332968	Trial comparisons
Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs)	352 of 371	347 of 369	740	NCT01724021	Trial comparisons
Arm A vs Arm B: serious adverse events	126 of 371	116 of 369	740	NCT01724021	Trial comparisons
Bortezomib + Rituximab vs Rituximab: serious adverse events	59 of 334	37 of 339	673	NCT00312845	Trial comparisons
Bortezomib + Rituximab vs Rituximab: Overall Response Rate	199 of 315	160 of 324	639	NCT00312845	Trial comparisons
GP2013 vs Rituximab: To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths	29 of 312	31 of 315	627	NCT01419665	Trial comparisons
GP2013 vs Rituximab: To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization	97 of 312	78 of 315	627	NCT01419665	Trial comparisons
GP2013 vs Rituximab: To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period	46 of 311	42 of 313	624	NCT01419665	Trial comparisons
GP2013 vs Rituximab: To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period	225 of 311	232 of 313	624	NCT01419665	Trial comparisons

1 to 10 of 154

See all 154 comparisons in its trials

Papers from its trials360

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40355425	RESULT	1	PubMed
38889737	RESULT	1	PubMed
38837078	RESULT	1	PubMed
37506346	RESULT	1	PubMed
36548927	RESULT	1	PubMed
33539729	RESULT	1	PubMed
32532790	RESULT	1	PubMed
31879945	RESULT	1	PubMed
31723798	RESULT	2	PubMed
30897038	RESULT	1	PubMed

1 to 10 of 360

See all 360 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018906

GET https://conductscience.org/api/diseases/v1/MONDO_0018906/drugs?page=2

API reference For AI assistants